Thiol-based drugs have also been shown to decrease the binding of SARS-CoV-2 S-proteins to ACE2, inhibit viral entry and infection, and significantly decrease lung neutrophilic inflammation [70,71]. This evidence concerns the gene ACE2 and infection.